657 related articles for article (PubMed ID: 18462867)
1. Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy.
Carew JS; Giles FJ; Nawrocki ST
Cancer Lett; 2008 Sep; 269(1):7-17. PubMed ID: 18462867
[TBL] [Abstract][Full Text] [Related]
2. Anticancer activities of histone deacetylase inhibitors.
Bolden JE; Peart MJ; Johnstone RW
Nat Rev Drug Discov; 2006 Sep; 5(9):769-84. PubMed ID: 16955068
[TBL] [Abstract][Full Text] [Related]
3. HDAC inhibitors, MS275 and SBHA, enhances cytotoxicity induced by oxaliplatin in the colorectal cancer cell lines.
Flis S; Gnyszka A; Spławiński J
Biochem Biophys Res Commun; 2009 Sep; 387(2):336-41. PubMed ID: 19596269
[TBL] [Abstract][Full Text] [Related]
4. Enhancing the apoptotic and therapeutic effects of HDAC inhibitors.
Frew AJ; Johnstone RW; Bolden JE
Cancer Lett; 2009 Aug; 280(2):125-33. PubMed ID: 19359091
[TBL] [Abstract][Full Text] [Related]
5. HDAC inhibitors for the treatment of cancer.
Secrist JP; Zhou X; Richon VM
Curr Opin Investig Drugs; 2003 Dec; 4(12):1422-7. PubMed ID: 14763127
[TBL] [Abstract][Full Text] [Related]
6. Histone deacetylation in epigenetics: an attractive target for anticancer therapy.
Mai A; Massa S; Rotili D; Cerbara I; Valente S; Pezzi R; Simeoni S; Ragno R
Med Res Rev; 2005 May; 25(3):261-309. PubMed ID: 15717297
[TBL] [Abstract][Full Text] [Related]
7. Histone deacetylase inhibitors enhance the chemosensitivity of tumor cells with cross-resistance to a wide range of DNA-damaging drugs.
Ozaki K; Kishikawa F; Tanaka M; Sakamoto T; Tanimura S; Kohno M
Cancer Sci; 2008 Feb; 99(2):376-84. PubMed ID: 18201278
[TBL] [Abstract][Full Text] [Related]
8. Regulation of apoptosis-associated genes by histone deacetylase inhibitors: implications in cancer therapy.
Jazirehi AR
Anticancer Drugs; 2010 Oct; 21(9):805-13. PubMed ID: 20679890
[TBL] [Abstract][Full Text] [Related]
9. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis via induction of 15-lipoxygenase-1 in colorectal cancer cells.
Hsi LC; Xi X; Lotan R; Shureiqi I; Lippman SM
Cancer Res; 2004 Dec; 64(23):8778-81. PubMed ID: 15574791
[TBL] [Abstract][Full Text] [Related]
10. Role of histone deacetylase inhibitors in the treatment of cancer (Review).
Mei S; Ho AD; Mahlknecht U
Int J Oncol; 2004 Dec; 25(6):1509-19. PubMed ID: 15547685
[TBL] [Abstract][Full Text] [Related]
11. HDAC inhibitors: a potential new category of anti-tumor agents.
Pan LN; Lu J; Huang B
Cell Mol Immunol; 2007 Oct; 4(5):337-43. PubMed ID: 17976313
[TBL] [Abstract][Full Text] [Related]
12. Development of histone deacetylase inhibitors for cancer treatment.
Marchion D; Münster P
Expert Rev Anticancer Ther; 2007 Apr; 7(4):583-98. PubMed ID: 17428177
[TBL] [Abstract][Full Text] [Related]
13. Histone deacetylase inhibitors--turning epigenic mechanisms of gene regulation into tools of therapeutic intervention in malignant and other diseases.
Riester D; Hildmann C; Schwienhorst A
Appl Microbiol Biotechnol; 2007 Jun; 75(3):499-514. PubMed ID: 17377788
[TBL] [Abstract][Full Text] [Related]
14. Protein deacetylases: enzymes with functional diversity as novel therapeutic targets.
Yoshida M; Shimazu T; Matsuyama A
Prog Cell Cycle Res; 2003; 5():269-78. PubMed ID: 14593721
[TBL] [Abstract][Full Text] [Related]
15. FK228 (depsipeptide): a HDAC inhibitor with pleiotropic antitumor activities.
Konstantinopoulos PA; Vandoros GP; Papavassiliou AG
Cancer Chemother Pharmacol; 2006 Nov; 58(5):711-5. PubMed ID: 16435156
[TBL] [Abstract][Full Text] [Related]
16. Histone deacetylase inhibitors in cancer therapy.
Lane AA; Chabner BA
J Clin Oncol; 2009 Nov; 27(32):5459-68. PubMed ID: 19826124
[TBL] [Abstract][Full Text] [Related]
17. Histone deacetylase inhibitors: biology and mechanism of action.
Mehnert JM; Kelly WK
Cancer J; 2007; 13(1):23-9. PubMed ID: 17464243
[TBL] [Abstract][Full Text] [Related]
18. Acetylation of proteins as novel target for antitumor therapy: review article.
Di Gennaro E; Bruzzese F; Caraglia M; Abruzzese A; Budillon A
Amino Acids; 2004 Jul; 26(4):435-41. PubMed ID: 15290351
[TBL] [Abstract][Full Text] [Related]
19. The molecular mechanism of HDAC inhibitors in anticancer effects.
Bi G; Jiang G
Cell Mol Immunol; 2006 Aug; 3(4):285-90. PubMed ID: 16978537
[TBL] [Abstract][Full Text] [Related]
20. Histone deacetylase inhibitors: molecular mechanisms of action.
Xu WS; Parmigiani RB; Marks PA
Oncogene; 2007 Aug; 26(37):5541-52. PubMed ID: 17694093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]